U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Name Type Language
ELEZANUMAB
INN  
INN  
Official Name English
elezanumab [INN]
Preferred Name English
ABT-555
Code English
IMMUNOGLOBULIN, ANTI-(REPULSIVE GUIDANCE MOLECULE RGMA) (HUMAN MONOCLONAL PR-1432051 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL PR-1432051 LIGHT CHAIN, DIMER
Systematic Name English
Elezanumab [WHO-DD]
Common Name English
AE12-1Y-QL
Code English
IMMUNOGLOBULIN G1-LAMBDA1, ANTI-(HOMO SAPIENS RGMA (REPULSIVE GUIDANCE MOLECULE FAMILY MEMBER A, REPULSIVE GUIDANCE MOLECULE A, RGMA)), HOMO SAPIENS MONOCLONAL ANTIBODY
Systematic Name English
IMMUNOGLOBULIN G1-LAMBDA 1, ANTI-(HOMO SAPIENS REPULSIVE GUIDANCE MOLECULE A)HOMO SAPIENS MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-18*01 (93%) (IGHD)-IGHJ3*01 (92%)) (8.8.13) (1-120)-HOMO SAPIENS IGHG1*01(CH2(L4>A(237),L5>A
Systematic Name English
ELEZANUMAB [USAN]
Common Name English
PR-1432051
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 729419
Created by admin on Tue Apr 01 16:45:20 GMT 2025 , Edited by admin on Tue Apr 01 16:45:20 GMT 2025
Code System Code Type Description
INN
10344
Created by admin on Tue Apr 01 16:45:20 GMT 2025 , Edited by admin on Tue Apr 01 16:45:20 GMT 2025
PRIMARY
CAS
1791416-49-3
Created by admin on Tue Apr 01 16:45:20 GMT 2025 , Edited by admin on Tue Apr 01 16:45:20 GMT 2025
PRIMARY
NCI_THESAURUS
C169936
Created by admin on Tue Apr 01 16:45:20 GMT 2025 , Edited by admin on Tue Apr 01 16:45:20 GMT 2025
PRIMARY
FDA UNII
SK1LVT23A1
Created by admin on Tue Apr 01 16:45:20 GMT 2025 , Edited by admin on Tue Apr 01 16:45:20 GMT 2025
PRIMARY
USAN
FG-10
Created by admin on Tue Apr 01 16:45:20 GMT 2025 , Edited by admin on Tue Apr 01 16:45:20 GMT 2025
PRIMARY
DRUG BANK
DB15240
Created by admin on Tue Apr 01 16:45:20 GMT 2025 , Edited by admin on Tue Apr 01 16:45:20 GMT 2025
PRIMARY
SMS_ID
100000174553
Created by admin on Tue Apr 01 16:45:20 GMT 2025 , Edited by admin on Tue Apr 01 16:45:20 GMT 2025
PRIMARY
ACTIVE MOIETY
ELEZANUMAB
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966